Click it and Unblock the Notifications
Latest Updates
-
PCOS Is Getting Younger: Why More Teenagers Are Being Diagnosed Than Ever Before -
National Nutrition Week 2026: What To Eat To How To Eat — Expert Shares 7 Ayurveda Rules For Mindful Nutrition -
Kareena Kapoor's Power Dressing At ‘Daayra’ Trailer Launch: 6 Bollywood Actresses Who Owned The Blazer Trend -
Dahi Handi 2026: Why Govindas Form Human Pyramids And What The Tradition Really Means -
Teachers Day 2026: 7 Things Students Can Teach Their Teachers In Return -
Happy Teacher's Day 2026: 100+ Wishes, Messages, and Captions To Say Thank You -
Teachers’ Day 2026: Dr Sarvepalli Radhakrishnan's Story And Why We Celebrate His Birthday -
New OTT Releases This Week (31 Aug-6 Sept): What To Watch Across Netflix, JioHotstar, Prime Video And SonyLiv -
Happy Janmashtami Wishes 2026: 50+ Quotes, Captions, Posts For Instagram, Facebook, WhatsApp And X -
Beyond Makhan Chor: 10 Lesser-Known Stories From Krishna's Childhood
EU Regulator Approves BioNTech-Pfizer Vaccine For Children In 5-11 Age Group
The European Medicines Agency, the EU's regulator for medicinal products, on Thursday approved the BioNTech-Pfizer vaccine, also known as Comirnaty, for children aged 5-11. It's the first vaccine approved for children under 12 in the 27-member EU.The vaccine has already been approved in the EU for use in people between the ages of 12 and 17 years since May and for adults since December 2020.
EMA said the vaccine should be given to children in two doses of 10 micrograms three weeks apart as an injection in the upper arm. Adult doses contain 30 micrograms. "The benefits of Comirnaty in children aged 5 to 11 outweigh the risks, particularly in those with conditions that increase the risk of severe COVID-19," EMA said.
Vaccinating children seen as key
The companies said a clinical trial of children aged 5 to 11 showed their vaccine to be 90.7% effective against the coronavirus. However, the studies have not been large enough to determine whether the vaccine could produce rare side effects such as chest and heart inflammation that have been seen in mostly male older teenagers and young adults after the second dose.
The approval for younger children comes as Europe battles another massive surge of COVID-19 cases. Authorities in Austria, which is seeing a very high rate of infections, did not wait for EMA approval and have already begun vaccinating the 5 to 11 age group.
In Germany and the Netherlands, children now account for the majority of cases, and experts say that vaccinating them could be vital to bringing the fourth wave of the pandemic under control. COVID-19 death in Germany reached 100,000 on Thursday.
What happens now?
EMA approval now has to be rubber-stamped by the EU's executive branch, the European Commission, before the vaccination can be rolled out for the 5-11 age group in EU member states. It typically follows EMA guidelines.
German Health Minister Jens Spahn said earlier this week that shipping of vaccines for younger children in the EU would begin on December 20. Germany's standing vaccination committee (STIKO) is due to issue its recommendation on vaccinating children aged 5-11 before the end of the year.
tj/msh (Reuters, AFP)
Continue with Google